Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering

Kathryn Michels(CTI BioPharma (United States)), Shon Green(CTI BioPharma (United States)), Susana Hernández(CTI BioPharma (United States)), Christopher J. Nicolai(Metis Design Corporation (United States)), Anai M. Perez(Fred Hutch Cancer Center), Ryan Larson(CTI BioPharma (United States)), Hung-An Ting(CTI BioPharma (United States)), Rich Getto(CTI BioPharma (United States)), Alissa Brandes(Unknown), Byoung Y. Ryu(CTI BioPharma (United States)), Alyssa Sheih(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Sarah Gould(Array BioPharma (United States)), Don Parrilla(CTI BioPharma (United States)), Mark D Pankau, Andrew M. Scharenberg(CTI BioPharma (Italy)), Blythe Irwin(CTI BioPharma (United States)), Timothy Gervascio(Seattle Children's Hospital), Seungjin Shin(Vector (United States)), Mason Muhonen(Array BioPharma (United States)), Alessandra M. Sullivan(CTI BioPharma (United States)), Jessica Freeman(Array BioPharma (United States))
Journal for ImmunoTherapy of Cancer
March 1, 2023
Cited by 108


Related Papers